Unknown PHASE1/PHASE2 INTERVENTIONAL 3-arm NCT03525652

Therapeutic Vaccine Plus PD-1 Knockout in Prostate Cancer Treatment

Clinical Assessment of a Therapeutic Vaccine in Combination With PD-1 Knockout T Cells in the Treatment of Prostate Cancer

Sponsor: Guangzhou Anjie Biomedical Technology Co., Ltd.

Conditions Prostate Cancer

Interventions PD-1 Knockout T Cells Therapeutic vaccine

Updated 6 times since 2018 Last updated: May 3, 2018 Started: Feb 22, 2018 Primary completion: Feb 22, 2021 Completion: Aug 30, 2021

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE1/PHASE2 clinical study on Prostate Cancer, this trial is ongoing. The trial is conducted by Guangzhou Anjie Biomedical Technology Co., Ltd. and has accumulated 6 data snapshots since 2018. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Unknown PHASE1/PHASE2
Jul 2024 — Sep 2024 [monthly]

Unknown PHASE1/PHASE2

Status: Unknown Status → Unknown · Phase: PHASE1_PHASE2 → PHASE1/PHASE2
Oct 2021 — Jul 2024 [monthly]

Unknown Status PHASE1_PHASE2

Status: Recruiting → Unknown Status
Jan 2021 — Oct 2021 [monthly]

Recruiting PHASE1_PHASE2
Nov 2018 — Jan 2021 [monthly]

Recruiting PHASE1_PHASE2

▶ Show 1 earlier version

Jun 2018 — Nov 2018 [monthly]

Recruiting PHASE1_PHASE2

First recorded

Feb 2018

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Guangzhou Anjie Biomedical Technology Co., Ltd.
The First Affiliated Hospital of Guangdong Pharmaceutical University
University of Technology, Sydney

Data source: The First Affiliated Hospital of Guangdong Pharmaceutical University

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Guangzhou, China